nach oben

memo - Magazine of European Medical Oncology

Tipp

Practice-changing strategies in the treatment of esophageal cancer

verfasst von: Ercan Müldür, MD, Wolfgang Hilbe, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the treatment of esophageal cancer. In this short review, five emerging studies are presented and discussed, which have changed standard of care in this disease.

Vorheriger Artikel Innovative strategies in metastatic gastric cancer: a short review

Nächster Artikel Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

International Agency for Research on Cancer, WHO. Globocan. China. 2020.

Arnold M, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–71. CrossRef

Hou H, et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. Front Oncol. 2019;9:548. CrossRef

van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. CrossRef

Sjoquist KM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy forresectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. CrossRef

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–1195. CrossRef

Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the checkmate 577 study. Ann Oncol. 2020;31(4):S1142–S215.

Kato K, Sun J, Shah MA. Pembrolizumab plus chemotherapy versus chemotherapy as first line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215.

10.

Chau I, Doki Y, Ajani JA, et al. Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the checkmate 648 study. 2021 ASCO Annual Meeting. 2021. Abstract 4001.

11.

Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48. CrossRef

12.

Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol. 2019;20:1506–17. CrossRef

13.

Xu RH, Luo H, Lu J, et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy vs chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2021; https://doi.org/10.1200/JCO.2021.39.15_suppl.4000. CrossRefPubMed

14.

Shen L, Lu Z‑H, Wang J‑Y, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastaticesophageal squamous cell cancer: first results of the phase III ORIENT-15 study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA52.

15.

Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric orgastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT- 16: first results of a randomized, double-blind,phase III study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA53.

Titel: Practice-changing strategies in the treatment of esophageal cancer
verfasst von: Ercan Müldür, MD
Wolfgang Hilbe, MD
Publikationsdatum: 22.12.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00779-1

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Practice-changing strategies in the treatment of esophageal cancer

Summary

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

Innovative strategies in gastrointestinal cancer

Toxicity management in severe and refractory cases—what we have learned

Cardiotoxicity—current recommendations of prevention and treatment

Palliative care: patient’s autonomy in the end-of-life situation